OptimizeRx appoints financial and operational experts
ROCHESTER, Mich., September 30, 2021 (GLOBE NEWSWIRE) – OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and continue treatment, announced the appointment of Edward Stelmakh as Chief Financial Officer ( CFO) and Chief Operating Officer (COO) effective October 11, 2021. He succeeds Doug Baker in the finance organization, who will remain executive vice president of finance and accounting.
“Ed’s broad financial expertise, operational experience and business analysis capabilities gained over the years leading the finance and operations teams of several growing public pharmaceutical companies are a perfect fit for our team, our clients and our growing partners ”, commented Will Febbo, CEO of OptimizeRx. “His in-depth understanding of our client base will be invaluable as we continue to develop and expand the value proposition we deliver to our life science partners as they strive to bring therapies to market. effective and efficient manner. As we continue to drive success for life science brands through patient education and enrollment programs, Ed’s pharmaceutical brand experience will significantly strengthen our leadership team.
Mr. Stelmakh is an accomplished senior executive with over 30 years of experience leading multiple areas of finance and operations in a variety of geographies and areas of the pharmaceutical industry. Adding operational guidance at the corporate leadership level ensures that all internal organizations ultimately remain ready for scalability and growth.
Mr. Stelmakh said, “I couldn’t be more impressed with the energy and passion of the management team at OptimizeRx, which is evident in the phenomenal growth they have driven over the past few years. As the healthcare industry turns to technology solutions as part of the go-to-market process, OptimizeRx continues to be at the forefront of this transition. I look forward to doing my part to support the strong growth prospects in 2021 and beyond. “
Stelmakh’s extensive experience in life sciences
Since 2015, Stelmakh has been CFO / COO at Otsuka America Pharmaceuticals Inc, the US division of the Japanese global healthcare company. During his tenure at Otsuka, Stelmakh’s role evolved from finance management as CFO of the US commercial division to the broader function of CFO / COO. In this role, he oversaw a team of several hundred people in the areas of finance, information technology, data and analytics, supply chain / manufacturing, strategy distribution, patient support services, alliance management, digital medicine and business operations. Stelmakh has played a major role in developing and executing a successful profitable growth strategy while overcoming significant market challenges including loss of exclusivity of Abilify, COVID-19 and acquisition and l integration of new companies, including Proteus Digital Health.
Prior to Otsuka, Stelmakh was Vice President of Financial Services, Clinical Development and Marketing at Covance (a division of LabCorp). He has also held various positions of increasing responsibility at Johnson & Johnson, Sanofi-Aventis, Organon / Schering-Plow and Mylan. His experience includes leadership roles in a wide range of financial, commercial, partnership / alliance governance and operational roles. Throughout his career, Stelmakh has boasted of bringing positive and lasting cultural change to his organizations.
Stelmakh received his Bachelor of Science in Finance from Towson University and his MBA from the University of Baltimore. He is also a Chartered Accountant (inactive) in the State of New Jersey and a Chartered Management Accountant. Outside of work, Stelmakh actively gives back to the community as treasurer and executive committee member of the American Foundation for Suicide Prevention in New York City and as a member of the advisory committee of the Princeton Arts Council.
Mr. Febbo concluded: “Just as important as the appointment of Ed as CFO, we are also very pleased to note that Doug Baker will remain involved in our finance organization and will continue as Executive Vice President of Finance. finance and accounting. As we gain critical mass, we stand a chance to maintain continuity as Doug will focus on developing our financial processes and controls in anticipation of the significant growth that lies ahead. This transition is a testament to Doug’s constant guidance throughout our first phase of significant growth, which has positioned us well to continue in the same vein.
OptimizeRx is the premier healthcare technology company enabling care-driven engagement between life science organizations, healthcare providers and patients at critical times throughout the patient care journey. Connecting more than 60% of U.S. healthcare providers and millions of their patients through a proprietary point-of-service network, connectivity is made easy with its Therapy initiation and persistence platform. This powerful platform of digital healthcare solutions is transforming the market and patient access with the life sciences market by unlocking:
- AI-driven real-time HCP marketing to raise awareness of treatment benefits to give patients a timely start to therapy
- Streamlined communication and processes around therapy initiation to reduce dropout through streamlined enrollment
- Successful, personalized enrollment programs to help patients stay on their doctor-recommended treatment
For more information, follow the company on Twitter, LinkedIn or visit www.optimizerx.com.
Important Cautions Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements should not be used in making an investment decision. The words “estimate”, “possible” and “research” and similar expressions identify forward-looking statements, which speak only as of the date on which the statement was made. The company assumes no obligation to publicly update or revise forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those stated, contemplated or underlying forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulations, competition and other material risks.
Andy D’Silva, Senior Vice President of Corporate Finance
Maira Alejandra, Head of Media Relations
Phone (754) 245-7070
Investor Relations Contact
LifeSci Advisors, LLC